

BIOSIMILARS: GLOBAL MARKETS



BIO090B
January 2015

Shalini Shahani Dewan
Project Analyst

ISBN: 1-62296-030-0



BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

| TOPIC | PAGE NO. |
|--|-----------------|
| CHAPTER 1 INTRODUCTION | 2 |
| STUDY OBJECTIVES | 2 |
| REASONS FOR DOING THIS STUDY | 2 |
| INTENDED AUDIENCE | 2 |
| SCOPE OF THE STUDY | 2 |
| METHODOLOGY | 3 |
| INFORMATION SOURCES | 3 |
| ANALYSTS' CREDENTIALS | 3 |
| RELATED BCC RESEARCH REPORTS | 4 |
| BCC RESEARCH WEBSITE | 4 |
| DISCLAIMER | 5 |
| CHAPTER 2 EXECUTIVE SUMMARY | 7 |
| <i>SUMMARY TABLE GLOBAL REVENUES FOR BIOSIMILARS BY TYPE, THROUGH 2019 (\$ MILLIONS)</i> | 8 |
| <i>SUMMARY FIGURE GLOBAL REVENUES FOR BIOSIMILARS BY TYPE, 2012-2019 (\$ MILLIONS)</i> | 9 |
| CHAPTER 3 OVERVIEW | 11 |
| WHO TERMINOLOGY RELATED TO BIOSIMILARS | 11 |
| BIOSIMILAR | 11 |
| BIOSIMILARITY | 11 |
| COMPARABILITY EXERCISE | 11 |
| EQUIVALENT | 11 |
| HEAD-TO-HEAD COMPARISON | 11 |
| ORIGINATOR PRODUCT | 12 |
| PHARMACOVIGILANCE | 12 |
| REFERENCE BIOTHERAPEUTIC PRODUCT (RBP) | 12 |
| SIMILAR BIOTHERAPEUTIC PRODUCT (SBP) | 12 |
| WELL-ESTABLISHED BIOTHERAPEUTIC PRODUCT | 12 |
| FDA TERMINOLOGY RELATED TO BIOSIMILARS | 12 |
| BIOLOGIC LICENSE APPLICATION (BLA) | 12 |
| BIOLOGICAL PRODUCT | 13 |
| BIOSIMILAR | 13 |
| BRAND NAME | 13 |
| THERAPEUTIC BIOLOGICAL PRODUCT | 13 |
| THERAPEUTIC EQUIVALENCE (TE) | 13 |
| <i>TABLE 1 BIOSIMILARS TERMINOLOGY</i> | 14 |
| DIFFERENCES BETWEEN SMALL-MOLECULE DRUGS AND BIOLOGICS | 14 |
| <i>TABLE 2 DIFFERENCES BETWEEN SMALL MOLECULES AND BIOLOGICS</i> | 15 |
| BIOSIMILARS VERSUS GENERICS | 15 |
| <i>TABLE 3 BIOSIMILARS VERSUS SMALL MOLECULE GENERICS</i> | 16 |
| MANUFACTURING OF BIOLOGICS | 17 |
| NATURAL SOURCING AND EXTRACTION | 18 |
| MICROBIAL FERMENTATION | 19 |
| TRANSGENICS | 19 |

| TOPIC | PAGE NO. |
|--|-----------------|
| CELL CULTURE | 20 |
| Mammalian Cell Culture | 20 |
| Other Cell Culture Systems | 21 |
| DEVELOPMENT OF BIOSIMILARS | 21 |
| DEVELOPMENT OF A HIGHLY SIMILAR PRODUCT | 21 |
| VALIDATING A BIOSIMILAR | 22 |
| CLASSES OF APPROVED BIOSIMILARS | 22 |
| HUMAN GROWTH HORMONES | 22 |
| <i>TABLE 4 BIOSIMILAR HUMAN GROWTH HORMONES</i> | 23 |
| GRANULOCYTE COLONY-STIMULATING FACTOR | 23 |
| <i>TABLE 5 G-CSF BIOSIMILARS</i> | 24 |
| ERYTHROPOIETIN | 24 |
| <i>TABLE 6 ERYTHROPOIETIN BIOSIMILARS</i> | 25 |
| INSULIN | 25 |
| <i>TABLE 7 INSULIN BIOSIMILARS</i> | 26 |
| MONOCLONAL ANTIBODIES | 26 |
| <i>TABLE 8 MONOCLONAL ANTIBODY BIOSIMILARS</i> | 27 |
| FOLLICLE-STIMULATING HORMONE | 27 |
| <i>TABLE 9 FSH BIOSIMILAR</i> | 28 |
| CHAPTER 4 REGULATORY ASPECTS | 30 |
| EUROPE REGULATIONS | 30 |
| UNITED STATES REGULATIONS | 32 |
| BIOSIMILAR REGULATIONS IN EMERGING MARKETS | 33 |
| GUIDELINES FOR BIOSIMILAR DEVELOPMENT IN JAPAN | 34 |
| GUIDELINES FOR BIOSIMILAR DEVELOPMENT IN INDIA | 35 |
| NAMING OF BIOSIMILARS | 35 |
| SIGNIFICANT REGULATORY ACTIVITIES | 35 |
| <i>TABLE 10 NEW MARKETING AUTHORIZATION OF BIOSIMILARS IN THE EUROPEAN UNION, 2010-AUGUST 2014</i> | 38 |
| CHAPTER 5 NEW DEVELOPMENTS | 40 |
| <i>TABLE 11 COMPANIES WITH BIOSIMILARS IN THE PIPELINE</i> | 40 |
| MOST POPULAR BIOSIMILAR TARGETS | 42 |
| ADALIMUMAB | 43 |
| <i>TABLE 12 HUMIRA (ADALIMUMAB) BIOSIMILARS IN CLINICAL TRIALS</i> | 43 |
| INFLIXIMAB | 43 |
| <i>TABLE 13 REMICADE (INFLIXIMAB) BIOSIMILARS IN CLINICAL TRIALS</i> | 44 |
| RITUXIMAB | 44 |
| <i>TABLE 14 RITUXAN (RITUXIMAB) BIOSIMILARS IN CLINICAL TRIALS</i> | 44 |
| BEVACIZUMAB | 44 |
| <i>TABLE 15 AVASTIN (BEVACIZUMAB) BIOSIMILARS IN CLINICAL TRIALS</i> | 45 |
| TRASTUZUMAB | 45 |
| <i>TABLE 16 HERCEPTIN (TRASTUZUMAB) BIOSIMILARS IN CLINICAL TRIALS</i> | 45 |
| OTHER BIOSIMILARS IN CLINICAL TRIALS | 46 |
| <i>TABLE 17 OTHER BIOSIMILARS IN CLINICAL TRIALS</i> | 46 |
| CHAPTER 6 TECHNOLOGY TRENDS | 48 |

| TOPIC | PAGE NO. |
|---|-----------------|
| EMERGING TRENDS IN BIOSIMILAR MANUFACTURING PROCESSES | 48 |
| EMERGING TRENDS IN ANALYTICAL TECHNOLOGIES | 51 |
| <i>TABLE 18 ANALYTICAL METHODS RECOGNIZED BY REGULATORY BODIES FOR COMPARABILITY EXERCISE AND RISK MITIGATION</i> | 51 |
| POLYACRYLAMIDE GEL ELECTROPHORESIS (PAGE) AND WESTERN BLOTTING | 52 |
| ISOELECTRIC FOCUSING (IEF)/PROTEIN BLOTTING | 53 |
| CAPILLARY ZONE ELECTROPHORESIS (CZE) | 53 |
| HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) | 53 |
| SPECTROSCOPIC TECHNIQUES | 53 |
| MASS SPECTROMETRY (MS) | 54 |
| IN VITRO ASSAYS | 54 |
| EPITOPE MAPPING | 55 |
| DIFFERENTIAL SCANNING CALORIMETRY (DSC) | 55 |
| CHAPTER 7 MARKET ANALYSIS | 57 |
| MARKET BY TYPE | 57 |
| MARKET OVERVIEW | 58 |
| MARKET REVENUE | 59 |
| <i>TABLE 19 GLOBAL REVENUES FOR BIOSIMILARS BY TYPE, THROUGH 2019 (\$ MILLIONS)</i> | 60 |
| <i>FIGURE 1 GLOBAL REVENUES FOR BIOSIMILARS BY TYPE, 2012-2019 (\$ MILLIONS)</i> | 60 |
| MARKET SHARE | 60 |
| <i>TABLE 20 MARKET SHARE OF BIOSIMILARS BY TYPE, IN 2013 (%)</i> | 61 |
| <i>FIGURE 2 MARKET SHARE OF BIOSIMILARS BY TYPE, IN 2013 (%)</i> | 61 |
| MARKET BY REGION | 61 |
| MARKET OVERVIEW | 62 |
| MARKET REVENUE | 63 |
| <i>TABLE 21 GLOBAL REVENUES FOR BIOSIMILARS BY REGION, THROUGH 2019 (\$ MILLIONS)</i> | 64 |
| <i>FIGURE 3 GLOBAL REVENUES FOR BIOSIMILARS BY REGION, 2012-2019 (\$ MILLIONS)</i> | 64 |
| MARKET SHARE | 64 |
| <i>TABLE 22 MARKET SHARE OF BIOSIMILARS BY REGION, IN 2013 (%)</i> | 65 |
| <i>FIGURE 4 MARKET SHARE OF BIOSIMILARS BY REGION, IN 2013 (%)</i> | 65 |
| ERYTHROPOIETINS (EPO) | 65 |
| Market Overview | 65 |
| Market Revenue | 66 |
| <i>TABLE 23 REVENUE FOR BIOSIMILAR ERYTHROPOIETINS BY REGION, THROUGH 2019 (\$ MILLIONS)</i> | 67 |
| <i>FIGURE 5 REVENUE FOR BIOSIMILAR ERYTHROPOIETINS BY REGION, 2012-2019 (\$ MILLIONS)</i> | 68 |
| Market Share | 68 |
| <i>TABLE 24 MARKET SHARE OF BIOSIMILAR ERYTHROPOIETINS BY REGION, 2013 (%)</i> | 68 |
| <i>FIGURE 6 MARKET SHARE OF BIOSIMILAR ERYTHROPOIETINS BY REGION, 2013 (%)</i> | 68 |
| HUMAN GROWTH HORMONES (HGH) | 69 |
| Market Overview | 69 |
| Market Revenue | 70 |

| TOPIC | PAGE NO. |
|--|-----------------|
| <i>TABLE 25 REVENUE FOR BIOSIMILAR HUMAN GROWTH HORMONES BY REGION, THROUGH 2019 (\$ MILLIONS)</i> | 71 |
| <i>FIGURE 7 REVENUE FOR BIOSIMILAR HUMAN GROWTH HORMONES BY REGION, 2012-2019 (\$ MILLIONS)</i> | 71 |
| Market Shares | 72 |
| <i>TABLE 26 MARKET SHARE OF BIOSIMILAR HUMAN GROWTH HORMONES BY REGION, 2013 (%)</i> | 72 |
| <i>FIGURE 8 MARKET SHARE OF BIOSIMILAR HUMAN GROWTH HORMONES BY REGION, 2013 (%)</i> | 72 |
| GRANULOCYTE COLONY-STIMULATING FACTORS (G-CSF) | 72 |
| Market Overview | 73 |
| Market Revenue | 73 |
| <i>TABLE 27 REVENUE FOR G-CSF BY REGION, THROUGH 2019 (\$ MILLIONS)</i> | 74 |
| <i>FIGURE 9 REVENUE FOR G-CSF BY REGION, 2012-2019 (\$ MILLIONS)</i> | 74 |
| Market Share | 75 |
| <i>TABLE 28 MARKET SHARE OF BIOSIMILAR G-CSF BY REGION, IN 2013 (%)</i> | 75 |
| <i>FIGURE 10 MARKET SHARE OF BIOSIMILAR G-CSF BY REGION, IN 2013 (%)</i> | 75 |
| LOW-MOLECULAR-WEIGHT HEPARIN (LMWH) | 75 |
| Market Overview | 76 |
| Market Revenue | 76 |
| <i>TABLE 29 REVENUE FOR LMWH BY REGION, THROUGH 2019 (\$ MILLIONS)</i> | 77 |
| <i>FIGURE 11 REVENUE FOR LMWH BY REGION, THROUGH 2019 (\$ MILLIONS)</i> | 77 |
| Market Share | 77 |
| <i>TABLE 30 MARKET SHARE OF BIOSIMILAR LMWH BY REGION, 2013 (%)</i> | 77 |
| <i>FIGURE 12 MARKET SHARE OF BIOSIMILAR LMWH BY REGION, 2013 (%)</i> | 78 |
| OTHER BIOSIMILARS | 78 |
| Market Overview | 79 |
| Market Revenue | 81 |
| <i>TABLE 31 REVENUE FOR OTHER BIOSIMILARS BY REGION, THROUGH 2019 (\$ MILLIONS)</i> | 82 |
| <i>FIGURE 13 REVENUE FOR OTHER BIOSIMILARS BY REGION, THROUGH 2019 (\$ MILLIONS)</i> | 82 |
| Market Share | 82 |
| <i>TABLE 32 MARKET SHARE OF OTHER BIOSIMILARS BY REGION, 2013 (%)</i> | 83 |
| <i>FIGURE 14 MARKET SHARE OF OTHER BIOSIMILARS BY REGION, 2013 (%)</i> | 83 |
| CHAPTER 8 INDUSTRY STRUCTURE | 85 |
| ERYTHROPOIETINS | 85 |
| MARKET LEADERS | 85 |
| <i>TABLE 33 LEADING MANUFACTURERS/ SUPPLIERS OF ERYTHROPOIETIN (EPO) BIOSIMILARS, 2013</i> | 85 |
| MARKET SHARE | 85 |
| <i>TABLE 34 MARKET SHARES OF MANUFACTURERS/SUPPLIERS FOR EPO BIOSIMILARS, 2013 (%)</i> | 85 |
| <i>FIGURE 15 MARKET SHARES OF MANUFACTURERS/SUPPLIERS FOR EPO BIOSIMILARS, 2013 (%)</i> | 86 |
| HUMAN GROWTH HORMONES | 86 |
| MARKET LEADERS | 86 |

| TOPIC | PAGE NO. |
|--|-----------------|
| <i>TABLE 35 LEADING MANUFACTURERS/SUPPLIERS OF HUMAN GROWTH HORMONES (HGH) BIOSIMILARS, 2013</i> | 86 |
| MARKET SHARE | 87 |
| <i>TABLE 36 MARKET SHARES OF MANUFACTURERS/SUPPLIERS FOR HGH BIOSIMILARS, 2013 (%)</i> | 87 |
| <i>FIGURE 16 MARKET SHARES OF MANUFACTURERS/SUPPLIERS FOR HGH BIOSIMILARS, 2013 (%)</i> | 88 |
| GRANULOCYTE COLONY-STIMULATING FACTOR | 88 |
| MARKET LEADERS | 88 |
| <i>TABLE 37 LEADING MANUFACTURERS/ SUPPLIERS OF G-CSF BIOSIMILARS, 2013</i> | 88 |
| MARKET SHARE | 89 |
| <i>TABLE 38 MARKET SHARES OF MANUFACTURERS/ SUPPLIERS FOR G-CSF BIOSIMILARS, 2013 (%)</i> | 89 |
| <i>FIGURE 17 MARKET SHARES OF MANUFACTURERS/ SUPPLIERS FOR G-CSF BIOSIMILARS, 2013 (%)</i> | 89 |
| LOW-MOLECULAR-WEIGHT HEPARINS | 90 |
| MARKET LEADERS | 90 |
| <i>TABLE 39 LEADING MANUFACTURERS/SUPPLIERS OF LMWH BIOSIMILARS, 2013</i> | 90 |
| MARKET SHARES | 91 |
| <i>TABLE 40 MARKET SHARES OF MANUFACTURERS/SUPPLIERS FOR LMWH BIOSIMILARS, 2013 (%)</i> | 91 |
| <i>FIGURE 18 MARKET SHARES OF MANUFACTURERS/ SUPPLIERS FOR LMWH BIOSIMILARS, 2013 (%)</i> | 91 |
| OTHER BIOSIMILARS | 92 |
| MARKET LEADERS | 92 |
| <i>TABLE 41 LEADING MANUFACTURERS/SUPPLIERS OF OTHER BIOSIMILARS, 2013</i> | 92 |
| MARKET SHARES | 93 |
| <i>TABLE 42 MARKET SHARES OF MANUFACTURERS/SUPPLIERS FOR OTHER BIOSIMILARS, 2013 (%)</i> | 93 |
| <i>FIGURE 19 MARKET SHARES OF MANUFACTURERS/ SUPPLIERS FOR OTHER BIOSIMILARS, 2013 (%)</i> | 94 |
| CHAPTER 9 PATENT ANALYSIS | 96 |
| UNITED STATES PATENTS | 96 |
| PATENTS BY YEAR | 96 |
| <i>TABLE 43 NUMBER OF SIGNIFICANT PATENTS BY YEAR, JANUARY 2010-AUGUST 2014</i> | 97 |
| <i>FIGURE 20 NUMBER OF SIGNIFICANT PATENTS BY YEAR, JANUARY 2010-AUGUST 2014</i> | 97 |
| PATENTS BY TYPE/CATEGORY | 97 |
| <i>TABLE 44 NUMBER OF U.S. PATENTS BY CATEGORY, JANUARY 2010-AUGUST 2014</i> | 98 |
| <i>FIGURE 21 NUMBER OF U.S. PATENTS BY CATEGORY, JANUARY 2010-AUGUST 2014</i> | 98 |
| PATENTS BY COMPANY | 99 |
| <i>TABLE 45 NUMBER OF U.S. PATENTS BY COMPANY, JANUARY 2010-AUGUST 2014</i> | 99 |
| PATENTS BY COUNTRY | 99 |
| <i>TABLE 46 NUMBER OF U.S. PATENTS BY COUNTRY, JANUARY 2010-AUGUST 2014</i> | 100 |
| <i>TABLE 47 PATENT SHARES BY COUNTRY, JANUARY 2010-AUGUST 2014 (NO./%)</i> | 100 |
| <i>FIGURE 22 PATENT SHARES BY COUNTRY, JANUARY 2010-AUGUST 2014 (%)</i> | 101 |
| EUROPEAN PATENTS | 101 |
| PATENTS BY YEAR | 101 |

| TOPIC | PAGE NO. |
|--|-----------------|
| <i>TABLE 48 NUMBER OF SIGNIFICANT PATENTS BY YEAR, JANUARY 2010-AUGUST 2014</i> | 101 |
| <i>FIGURE 23 NUMBER OF SIGNIFICANT PATENTS BY YEAR, JANUARY 2010-AUGUST 2014</i> | 101 |
| PATENTS BY TYPE/ CATEGORY | 102 |
| <i>TABLE 49 NUMBER OF PATENTS BY CATEGORY, JANUARY 2010-AUGUST 2014</i> | 102 |
| PATENTS BY COMPANY | 103 |
| <i>TABLE 50 NUMBER OF PATENTS BY COMPANY, JANUARY 2010-AUGUST 2014</i> | 103 |
| PATENTS BY COUNTRY | 103 |
| <i>TABLE 51 NUMBER OF PATENTS BY COUNTRY, JANUARY 2010-AUGUST 2014</i> | 104 |
| <i>TABLE 52 PATENT SHARES BY COUNTRY, JANUARY 2010-AUGUST 2014 (NO./%)</i> | 104 |
| <i>FIGURE 24 PATENT SHARES BY COUNTRY, JANUARY 2010-AUGUST 2014 (%)</i> | 105 |
| CHAPTER 10 CURRENT SITUATION | 107 |
| INCREASING DISEASE BURDEN DRIVING THE MARKET | 107 |
| AGING POPULATION | 107 |
| STRONG GOVERNMENT SUPPORT | 107 |
| PATENT EXPIRATION | 108 |
| <i>TABLE 53 SIGNIFICANT PATENT EXPIRATIONS OF BIOLOGICS</i> | 108 |
| COLLABORATIONS/ PARTNERSHIPS | 108 |
| ELECTRONIC COMPANIES ENTERING THE BIOSIMILARS SECTOR WITH SIGNIFICANT INVESTMENTS | 109 |
| MARKET FACTORS IN EMERGING MARKETS | 109 |
| LESS STRINGENT REGULATORY REQUIREMENTS | 110 |
| COMPETITION | 110 |
| HIGH COST AND AVAILABILITY ISSUES | 110 |
| LACK OF EXPERTISE IN THE PRODUCTION OF HIGHLY DEMANDING PRODUCTS SUCH AS MONOCLONAL ANTIBODIES | 111 |
| RISING INVESTMENTS IN INDIAN BIOSIMILARS SECTOR | 111 |
| CHAPTER 11 COMPANY PROFILES | 113 |
| 3SBIO INC. | 113 |
| ACTAVIS INC. LTD. | 113 |
| AMOYTOP BIOTECH CO., LTD. | 114 |
| ANHUI ANKE BIOTECHNOLOGY (GROUP) CO. LTD. | 115 |
| APOTEX INC. | 115 |
| AVESTHAGEN LIMITED | 115 |
| BHARAT SERUMS AND VACCINES LTD. | 116 |
| BIOCON LTD. | 116 |
| BIOXPRESS THERAPEUTICS SA | 117 |
| BIOTON S. A. | 118 |
| BLAU FARMACEUTICA S/A | 118 |
| BOEHRINGER INGELHEIM | 118 |
| CELLTRION GROUP | 119 |
| CHINA NATIONAL BIOTECH CORP. (CNBC) | 119 |
| CIPLA LIMITED | 120 |
| CINNAGEN | 120 |
| CJSC BIOCAD | 121 |

| TOPIC | PAGE NO. |
|--|-----------------|
| DONG-A PHARMACEUTICAL CO. LTD. | 121 |
| DR. REDDY'S LABORATORIES LTD. | 122 |
| EMCURE PHARMACEUTICALS LTD. | 122 |
| FERON LIMITED | 123 |
| FINOX BIOTECH | 123 |
| FUJIFILM DIOSYNTH BIOTECHNOLOGIES | 124 |
| GEDEON RICHTER PLC | 124 |
| GENESCENCE PHARMACEUTICALS CO. LTD. | 125 |
| GENEXINE INC. | 125 |
| GH GENHELIX S A | 126 |
| GREEN CROSS LIFE SCIENCE CORP. | 126 |
| HANALL PHARMACEUTICALS | 127 |
| HANGZHOU JIUYUAN GENE ENGINEERING CO. LTD. | 127 |
| HANWHA CHEMICAL CORP. | 128 |
| HOSPIRA INC. | 128 |
| INTAS BIOPHARMACEUTICALS LTD | 129 |
| JCR PHARMACEUTICALS CO. LTD. | 130 |
| KISSEI PHARMACEUTICAL CO. LTD. | 130 |
| LG LIFE SCIENCES | 131 |
| MEDICE ARZNEIMITTEL PUTTER GMBH AND CO. KG | 131 |
| MERCK BIOVENTURES | 132 |
| MJ BIOPHARM PVT. LTD. | 132 |
| MOMENTA PHARMACEUTICALS | 133 |
| MYCENAX BIOTECH INC. | 133 |
| NANOGEN BIOPHARMACEUTICAL | 133 |
| NCPC GENETECH BIOTECHNOLOGY CO. LTD. | 134 |
| NEUCLONE | 134 |
| NIPPON KAYAKU CO. LTD. | 135 |
| PHARMAPARK LLC | 135 |
| PLANTFORM CORP. | 136 |
| PROBIOMED, S.A. DE C.V. | 136 |
| RANBAXY LABORATORIES LTD. | 137 |
| RELIANCE LIFE SCIENCES | 138 |
| SAMSUNG BIOLOGICS | 139 |
| SANDOZ INTERNATIONAL GMBH | 139 |
| SCINOPHARM TAIWAN LTD. | 140 |
| SOTEX PHARMACEUTICALS | 140 |
| STADA ARZNEIMITTEL AG | 141 |
| TEVA PHARMACEUTICALS INDUSTRIES LTD | 141 |
| TIANJIN HUALIDA BIOTECHNOLOGY LTD | 142 |
| USV LIMITED | 142 |
| WOCKHARDT LIMITED | 143 |
| ZHONGSHANHYGENE BIOPHARMA CO. LTD. | 143 |
| CHAPTER 12 APPENDIX I-ABBREVIATIONS | 146 |

LIST OF TABLES

| TABLE HEADING | PAGE NO. |
|--|-----------------|
| SUMMARY TABLE GLOBAL REVENUES FOR BIOSIMILARS BY TYPE, THROUGH 2019 (\$ MILLIONS) | 8 |
| TABLE 1 BIOSIMILARS TERMINOLOGY | 14 |
| TABLE 2 DIFFERENCES BETWEEN SMALL MOLECULES AND BIOLOGICS | 15 |
| TABLE 3 BIOSIMILARS VERSUS SMALL MOLECULE GENERICS | 16 |
| TABLE 4 BIOSIMILAR HUMAN GROWTH HORMONES | 23 |
| TABLE 5 G-CSF BIOSIMILARS | 24 |
| TABLE 6 ERYTHROPOIETIN BIOSIMILARS | 25 |
| TABLE 7 INSULIN BIOSIMILARS | 26 |
| TABLE 8 MONOCLONAL ANTIBODY BIOSIMILARS | 27 |
| TABLE 9 FSH BIOSIMILAR | 28 |
| TABLE 10 NEW MARKETING AUTHORIZATION OF BIOSIMILARS IN THE EUROPEAN UNION, 2010-AUGUST 2014 | 38 |
| TABLE 11 COMPANIES WITH BIOSIMILARS IN THE PIPELINE | 40 |
| TABLE 12 HUMIRA (ADALIMUMAB) BIOSIMILARS IN CLINICAL TRIALS | 43 |
| TABLE 13 REMICADE (INFLIXIMAB) BIOSIMILARS IN CLINICAL TRIALS | 44 |
| TABLE 14 RITUXAN (RITUXIMAB) BIOSIMILARS IN CLINICAL TRIALS | 44 |
| TABLE 15 AVASTIN (BEVACIZUMAB) BIOSIMILARS IN CLINICAL TRIALS | 45 |
| TABLE 16 HERCEPTIN (TRASTUZUMAB) BIOSIMILARS IN CLINICAL TRIALS | 45 |
| TABLE 17 OTHER BIOSIMILARS IN CLINICAL TRIALS | 46 |
| TABLE 18 ANALYTICAL METHODS RECOGNIZED BY REGULATORY BODIES FOR COMPARABILITY EXERCISE AND RISK MITIGATION | 51 |
| TABLE 19 GLOBAL REVENUES FOR BIOSIMILARS BY TYPE, THROUGH 2019 (\$ MILLIONS) | 60 |
| TABLE 20 MARKET SHARE OF BIOSIMILARS BY TYPE, IN 2013 (%) | 61 |
| TABLE 21 GLOBAL REVENUES FOR BIOSIMILARS BY REGION, THROUGH 2019 (\$ MILLIONS) | 64 |
| TABLE 22 MARKET SHARE OF BIOSIMILARS BY REGION, IN 2013 (%) | 65 |
| TABLE 23 REVENUE FOR BIOSIMILAR ERYTHROPOIETINS BY REGION, THROUGH 2019 (\$ MILLIONS) | 67 |
| TABLE 24 MARKET SHARE OF BIOSIMILAR ERYTHROPOIETINS BY REGION, 2013 (%) | 68 |
| TABLE 25 REVENUE FOR BIOSIMILAR HUMAN GROWTH HORMONES BY REGION, THROUGH 2019 (\$ MILLIONS) | 71 |
| TABLE 26 MARKET SHARE OF BIOSIMILAR HUMAN GROWTH HORMONES BY REGION, 2013 (%) | 72 |
| TABLE 27 REVENUE FOR G-CSF BY REGION, THROUGH 2019 (\$ MILLIONS) | 74 |
| TABLE 28 MARKET SHARE OF BIOSIMILAR G-CSF BY REGION, IN 2013 (%) | 75 |
| TABLE 29 REVENUE FOR LMWH BY REGION, THROUGH 2019 (\$ MILLIONS) | 77 |
| TABLE 30 MARKET SHARE OF BIOSIMILAR LMWH BY REGION, 2013 (%) | 77 |
| TABLE 31 REVENUE FOR OTHER BIOSIMILARS BY REGION, THROUGH 2019 (\$ MILLIONS) | 82 |
| TABLE 32 MARKET SHARE OF OTHER BIOSIMILARS BY REGION, 2013 (%) | 83 |
| TABLE 33 LEADING MANUFACTURERS/ SUPPLIERS OF ERYTHROPOIETIN (EPO) BIOSIMILARS, 2013 | 85 |
| TABLE 34 MARKET SHARES OF MANUFACTURERS/SUPPLIERS FOR EPO BIOSIMILARS, 2013 (%) | 85 |
| TABLE 35 LEADING MANUFACTURERS/SUPPLIERS OF HUMAN GROWTH HORMONES (HGH) BIOSIMILARS, 2013 | 86 |

| TABLE HEADING | PAGE NO. |
|--|-----------------|
| TABLE 36 MARKET SHARES OF MANUFACTURERS/SUPPLIERS FOR HGH BIOSIMILARS, 2013 (%) | 87 |
| TABLE 37 LEADING MANUFACTURERS/ SUPPLIERS OF G-CSF BIOSIMILARS, 2013 | 88 |
| TABLE 38 MARKET SHARES OF MANUFACTURERS/ SUPPLIERS FOR G-CSF BIOSIMILARS, 2013 (%) | 89 |
| TABLE 39 LEADING MANUFACTURERS/SUPPLIERS OF LMWH BIOSIMILARS, 2013 | 90 |
| TABLE 40 MARKET SHARES OF MANUFACTURERS/SUPPLIERS FOR LMWH BIOSIMILARS, 2013 (%) | 91 |
| TABLE 41 LEADING MANUFACTURERS/SUPPLIERS OF OTHER BIOSIMILARS, 2013 | 92 |
| TABLE 42 MARKET SHARES OF MANUFACTURERS/SUPPLIERS FOR OTHER BIOSIMILARS, 2013 (%) | 93 |
| TABLE 43 NUMBER OF SIGNIFICANT PATENTS BY YEAR, JANUARY 2010-AUGUST 2014 | 97 |
| TABLE 44 NUMBER OF U.S. PATENTS BY CATEGORY, JANUARY 2010-AUGUST 2014 | 98 |
| TABLE 45 NUMBER OF U.S. PATENTS BY COMPANY, JANUARY 2010-AUGUST 2014 | 99 |
| TABLE 46 NUMBER OF U.S. PATENTS BY COUNTRY, JANUARY 2010-AUGUST 2014 | 100 |
| TABLE 47 PATENT SHARES BY COUNTRY, JANUARY 2010-AUGUST 2014 (NO./%) | 100 |
| TABLE 48 NUMBER OF SIGNIFICANT PATENTS BY YEAR, JANUARY 2010-AUGUST 2014 | 101 |
| TABLE 49 NUMBER OF PATENTS BY CATEGORY, JANUARY 2010-AUGUST 2014 | 102 |
| TABLE 50 NUMBER OF PATENTS BY COMPANY, JANUARY 2010-AUGUST 2014 | 103 |
| TABLE 51 NUMBER OF PATENTS BY COUNTRY, JANUARY 2010-AUGUST 2014 | 104 |
| TABLE 52 PATENT SHARES BY COUNTRY, JANUARY 2010-AUGUST 2014 (NO./%) | 104 |
| TABLE 53 SIGNIFICANT PATENT EXPIRATIONS OF BIOLOGICS | 108 |

LIST OF FIGURES

| FIGURE TITLE | PAGE NO. |
|--|-----------------|
| SUMMARY FIGURE GLOBAL REVENUES FOR BIOSIMILARS BY TYPE, 2012-2019 (\$ MILLIONS) | 9 |
| FIGURE 1 GLOBAL REVENUES FOR BIOSIMILARS BY TYPE, 2012-2019 (\$ MILLIONS) | 60 |
| FIGURE 2 MARKET SHARE OF BIOSIMILARS BY TYPE, IN 2013 (%) | 61 |
| FIGURE 3 GLOBAL REVENUES FOR BIOSIMILARS BY REGION, 2012-2019 (\$ MILLIONS) | 64 |
| FIGURE 4 MARKET SHARE OF BIOSIMILARS BY REGION, IN 2013 (%) | 65 |
| FIGURE 5 REVENUE FOR BIOSIMILAR ERYTHROPOIETINS BY REGION, 2012-2019 (\$ MILLIONS) | 68 |
| FIGURE 6 MARKET SHARE OF BIOSIMILAR ERYTHROPOIETINS BY REGION, 2013 (%) | 68 |
| FIGURE 7 REVENUE FOR BIOSIMILAR HUMAN GROWTH HORMONES BY REGION, 2012-2019 (\$ MILLIONS) | 71 |
| FIGURE 8 MARKET SHARE OF BIOSIMILAR HUMAN GROWTH HORMONES BY REGION, 2013 (%) | 72 |
| FIGURE 9 REVENUE FOR G-CSF BY REGION, 2012-2019 (\$ MILLIONS) | 74 |
| FIGURE 10 MARKET SHARE OF BIOSIMILAR G-CSF BY REGION, IN 2013 (%) | 75 |
| FIGURE 11 REVENUE FOR LMWH BY REGION, THROUGH 2019 (\$ MILLIONS) | 77 |
| FIGURE 12 MARKET SHARE OF BIOSIMILAR LMWH BY REGION, 2013 (%) | 78 |
| FIGURE 13 REVENUE FOR OTHER BIOSIMILARS BY REGION, THROUGH 2019 (\$ MILLIONS) | 82 |
| FIGURE 14 MARKET SHARE OF OTHER BIOSIMILARS BY REGION, 2013 (%) | 83 |
| FIGURE 15 MARKET SHARES OF MANUFACTURERS/SUPPLIERS FOR EPO BIOSIMILARS, 2013 (%) | 86 |
| FIGURE 16 MARKET SHARES OF MANUFACTURERS/SUPPLIERS FOR HGH BIOSIMILARS, 2013 (%) | 88 |
| FIGURE 17 MARKET SHARES OF MANUFACTURERS/ SUPPLIERS FOR G-CSF BIOSIMILARS, 2013 (%) | 89 |
| FIGURE 18 MARKET SHARES OF MANUFACTURERS/ SUPPLIERS FOR LMWH BIOSIMILARS, 2013 (%) | 91 |
| FIGURE 19 MARKET SHARES OF MANUFACTURERS/ SUPPLIERS FOR OTHER BIOSIMILARS, 2013 (%) | 94 |
| FIGURE 20 NUMBER OF SIGNIFICANT PATENTS BY YEAR, JANUARY 2010-AUGUST 2014 | 97 |
| FIGURE 21 NUMBER OF U.S. PATENTS BY CATEGORY, JANUARY 2010-AUGUST 2014 | 98 |
| FIGURE 22 PATENT SHARES BY COUNTRY, JANUARY 2010-AUGUST 2014 (%) | 101 |
| FIGURE 23 NUMBER OF SIGNIFICANT PATENTS BY YEAR, JANUARY 2010-AUGUST 2014 | 101 |
| FIGURE 24 PATENT SHARES BY COUNTRY, JANUARY 2010-AUGUST 2014 (%) | 105 |